Recombinant SARS-CoV-2 (2019-nCoV) Spike RBD protein

Measured by its binding ability in a functional ELISA with Human ACE-2 (CAT# ATGP3963)

RVQPTE SIVRFPNITN LCPFGEVFNA TRFASVYAWN RKRISNCVAD YSVLYNSASFSTFKCYGVSP TKLNDLCFTN VYADSFVIRG DEVRQIAPGQ TGKIADYNYK LPDDFTGCVI AWNSNNLDSK VGGNYNYLYR LFRKSNLKPF ERDISTEIYQ AGSTPCNGVE GFNCYFPLQS YGFQPTNGVG YQPYRVVVLS FELLHAPATV CGPKKSTNLV KNKCVNF

An epidemic of acute respiratory syndrome in humans, which appeared in Wuhan, China in December 2019, was caused by a novel coronavirus (SARS-CoV-2). This disease was named as "Coronavirus Disease 2019" (COVID-19). This virus shares highly homological sequence with SARS-CoV, and causes acute, highly lethal pneumonia coronavirus disease 2019 (COVID-19) with clinical symptoms similar to those reported for SARS-CoV and MERS-CoV. The genome of this and other emerging pathogenic human CoVs encodes four major structural proteins [spike (S), envelope (E), membrane (M), and nucleocapsid (N)], approximately 16 nonstructural proteins (nsp1-16), and five to eight accessory proteins. Among them, the S protein plays an essential role in viral attachment, fusion, entry, and transmission. It comprises an N-terminal S1 subunit responsible for virus-receptor binding and a C-terminal S2 subunit responsible for virus-cell membrane fusion. S1 is further divided into an N-terminal domain (NTD) and a receptor-binding domain (RBD). SARS-CoV-2 and SARS-CoV bind angiotensin-converting enzyme 2 (ACE2) while MERS-CoV binds dipeptidyl peptidase 4 (DPP4), as receptors on the host cell expressing ACE2 (e.g., pneumocytes, enterocytes) or DPP4 (e.g., liver or lung cells including Huh-7, MRC-5, and Calu-3). During infection, CoV first binds the host cell through interaction between its S1-RBD and the cell membrane receptor, triggering conformational changes in the S2 subunit that result in virus fusion and entry into the target cell. Recombinant SARS-CoV-2 (2019-nCoV) Spike RBD, fused to His-tag at C-terminus, was expressed in HEK293 cell and purified by using conventional chromatography techniques.

< 1 EU per 1ug of protein (determined by LAL method)

Liquid. In Phosphate-Buffered Saline (pH 7.4) containing 10% glycerol

Wu, F. et al. (2020) Nature. 579:265-269.; ; Ortega, J.T. et al. (2020) EXCLI J. 19:410-417.; ; Wanbo T., et al, (2020) Cell. Mol. Immunol. 17:613-620.; ; Gorbalenya A., et al (2020) Nat. Microbiol. 5:536-544.; ; Tortorici, M.A. and D. Veesler (2019). Adv. Virus Res. 105:93-116.

Asp